Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by WalkOverTheStrton Dec 15, 2023 10:47am
88 Views
Post# 35786635

RE:RE:Bonne Chance

RE:RE:Bonne Chance

Agree that sooner or later Alvira will need to give details on the price model with ascend so analysts can cover them (if they ever get there). Ascend is a small out for (40ish people listed on LinkedIn) around 13 witthin sales so it will very much depend on how incentivized from a pricing split ascend and their sellers are to push VMS as well how much effort they will put behind it. Ventripoint has one sales manger in the USA and one demo clinical person.  No sign they will ramp this up so there sales team is tiny. Execution  will be everything and getting away from device sales is needed. A year into Alvira's stint and two sales to show and no mention of any pos outstanding last investor call (she said she would not comment on advanced pos - question I asked). A lot of unanswered questions / details to play out.


I still have some confidence that they 1)  are slowly getting on track with a pivot to ascend  (tiny vendor / partner compared to GE) which seems to have a good reach in the USA and can move more quickly than GE HC. 2) recent Ollie Hinkle Heart foundation partnership. IHHF budget isn't large $1.5m a year and majority spent direct to patients and their families so I do not expect them to buy more than a handful of vms units if that but the intros to hospitals is needed as the USA sales manager imo needs to go. 3) capital being a manged ok but I expect a raise in Q1 or Q2. 4) 4.0 eliminates the pain point of the user placing the points which should help make VMS easier to use 

time will tell. Would like to get to my breakeven so o can start to off load some risk. 

<< Previous
Bullboard Posts
Next >>